Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Orforglipron Capsules and Tablets in Healthy Overweight and Obese Participants
NCT06440980Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of orforglipron in obesity (14 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval and Steady-state Maximum Observed Concentration. Started Jun 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06440980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440980.